WuXi Biologics Continues to Deliver Record Results

56.6% Year-on-Year Revenue Growth to RMB2,534.5 Million

Net Profit 249.6% of Same Period Last Year to RMB 630.5 Million

Adjusted Net Profit 173.6% of Same Period Last Year to RMB751.5 Million

Total Backlog Surged 146.2% to US$ 3.6 Billion

Continued to Gain Market Share and Added 57 New Integrated Projects

Total Integrated Projects Increased to 205 Including 13 Late-Phase Projects

Chinese Market Accelerated to 105.7% Growth in H2 2018

WuXiBodyTM Platform Successfully Launched

"Global Dual Sourcing within WuXi Bio" Demonstrated Success

Construction of All New Facilities on Track

Sufficient Capacities to Start any Project in 4 Weeks

 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is the leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of December 31, 2018, there were a total of 205 integrated projects, including 97 projects in pre-clinical development stage, 94 projects in early-phase (phase I and II) clinical development, 13 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network.